Merck Expands Oncology Pipeline With SpringWorks Deal – Merger Arbitrage Mondays
SpringWorks Therapeutics, Inc. (SWTX): $46.23
Market Cap: $3.47 B
Deal Value: $3.4 B
Germany’s Merck KGaA entered a merger agreement on April 28, 2025, to acquire U.S.-based SpringWorks Therapeutics in an all-cash deal valued at $3.4 billion.
Under the terms of the agreement, Merck KGaA will acquire SpringWorks for $47 per share in cash, representing a prem…
Keep reading with a 7-day free trial
Subscribe to The Special Situation Report to keep reading this post and get 7 days of free access to the full post archives.